Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 3,675 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Excision Clear all
Completed No phase listed Observational

Kidney Stone Structural Analysis By Helical Computed Tomography (CT)

NCT00169780
View directory record Official record
Conditions
Nephrolithiasis
Interventions
High definition helical CT (64 head scanner)
Radiation
Lead sponsor
Indiana Kidney Stone Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Oct 17, 2026, 7:10 PM EDT
Not listed Phase 1Phase 2 Interventional

Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation

NCT01983761
View directory record Official record
Conditions
Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma (NHL), Hodgkin's Lymphoma
Interventions
Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative), Fludarabine, Melphalan, ATG (Reduced Intensity)
Drug
Lead sponsor
Targazyme, Inc.
Industry
Eligibility
1 Year to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
4
States / cities
La Jolla, California • Cleveland, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 17, 2026, 7:10 PM EDT
Recruiting Early Phase 1 Interventional

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

NCT05804227
View directory record Official record
Conditions
Gliomas
Interventions
Ulixertinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 17, 2026, 7:10 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation

NCT02163824
View directory record Official record
Conditions
Ocular Infections, Irritations and Inflammations
Interventions
KPI-121 0.25%, KPI-121 1.0%, Vehicle of KPI-121 0.25%, Vehicle of KPI-121 1.0%
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
23
States / cities
Artesia, California • Mission Hills, California • Rancho Cordova, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 17, 2026, 7:10 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

High Resolution Pharyngeal Manometry (HRPM) Biofeedback

NCT07508059
View directory record Official record
Conditions
Healthy
Interventions
Swallowing Maneuvers, High Resolution Pharyngeal Manometry (HRPM)
Other · Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 17, 2026, 7:10 PM EDT
Completed No phase listed Observational

Incidence of Venous Thromboembolism in Patients Undergoing Major Esophageal Resection

NCT03115541
View directory record Official record
Conditions
Venous Thromboembolism, Thoracic Surgery, Esophageal Cancer
Interventions
Not listed
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 17, 2026, 7:10 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of Ambu® aScope™ 4 Cysto With the aView™ 2 Advance for Flexible Cystoscopy

NCT04829461
View directory record Official record
Conditions
Cystoscopy, Ureteral Stent
Interventions
Ambu® aScope™ 4 Cysto with the aView™ 2 Advance used for stent removal, Standard of care reusable cystoscope used for stent removal
Device
Lead sponsor
Ambu Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Hershey, Pennsylvania • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 17, 2026, 7:10 PM EDT
Completed Phase 2 Interventional

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

NCT03914794
View directory record Official record
Conditions
Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent
Interventions
Pemigatinib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Syracuse, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 17, 2026, 7:10 PM EDT
Completed Phase 3 Interventional

Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas

NCT00003216
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
106
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 17, 2026, 7:10 PM EDT
Withdrawn Not applicable Interventional

Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients

NCT01757158
View directory record Official record
Conditions
Lung Cancer
Interventions
Cs-131 brachytherapy seeds
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 17, 2026, 7:10 PM EDT
Not listed No phase listed Observational

Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.

NCT03630926
View directory record Official record
Conditions
Prostate Cancer, Benign Prostatic Hypertrophy, Bladder Stones, Kidney Stones
Interventions
NV-VPAC1 PCa Urine Diagnostic Test
Diagnostic Test
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 17, 2026, 7:10 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and GM-CSF in Biliary Cancer

NCT02703714
View directory record Official record
Conditions
Biliary Cancer
Interventions
Pembrolizumab, Sargramostim
Drug
Lead sponsor
Robin Kate Kelley
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 17, 2026, 7:10 PM EDT
Recruiting Not applicable Interventional

Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound

NCT05610852
View directory record Official record
Conditions
Prostate Adenocarcinoma, Prostate Cancer
Interventions
Transvesical Single Port Robotic Partial Prostatectomy, High-intensity focused ultrasound (HIFU)
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Male only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 17, 2026, 7:10 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

NCT05319015
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Neoadjuvant Lenvatinib, Neoadjuvant Pembrolizumab, Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection, Adjuvant Pembrolizumab
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 17, 2026, 7:10 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Feasibility of a Single-operator Peroral Cholangiopancreatioscopy System (SpyGlass)

NCT02776709
View directory record Official record
Conditions
Bile Duct Strictures, Common Bile Duct Stones
Interventions
ERCP with cholangioscopy
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
5
States / cities
Los Angeles, California • Denver, Colorado • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 17, 2026, 7:10 PM EDT
Recruiting Phase 3 Interventional

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

NCT06790784
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy (PDR)
Interventions
Vitrectomy, Endolaser, Faricimab, Panretinal Photocoagulation (PRP)
Procedure · Device · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
34
States / cities
Huntington Beach, California • Loma Linda, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 17, 2026, 7:10 PM EDT
Withdrawn Phase 3 Interventional

Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer

NCT03298958
View directory record Official record
Conditions
Bladder Cancer
Interventions
Rapamycin, Placebo Oral Tablet
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 17, 2026, 7:10 PM EDT
Completed Not applicable Interventional

Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus

NCT00614835
View directory record Official record
Conditions
Uterine Leiomyosarcoma, Uterine Cancer
Interventions
Docetaxel plus Gemcitabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Oct 17, 2026, 7:10 PM EDT
Withdrawn Not applicable Interventional

Patent Foramen Ovale (PFO) Closure at the Time of Endovascular Cardiac Electronic Device Implantation

NCT03232450
View directory record Official record
Conditions
Foramen Ovale, Patent
Interventions
Aspirin, Cardiovascular Implantable Device (CIED), Gore Cardioform Septal Occluder
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 17, 2026, 7:10 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Intercostal CryoAnalgesia in Robotic Lung Resection

NCT05144828
View directory record Official record
Conditions
Pain, Postoperative, Lung Diseases
Interventions
Intercostal Nerve Cryoablation, Patient-controlled analgesia (PCA)
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 17, 2026, 7:10 PM EDT
Recruiting Not applicable Interventional

Traction vs. No Traction in Colonic ESD

NCT06159634
View directory record Official record
Conditions
Gastrointestinal Neoplasm
Interventions
Endoscopic Submucosal Dissection, Traction Device
Procedure · Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 17, 2026, 7:10 PM EDT
Completed Phase 2 Interventional

Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast

NCT00165256
View directory record Official record
Conditions
Ductal Carcinoma in Situ of the Breast
Interventions
Observation
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 17, 2026, 7:10 PM EDT
Terminated Phase 3 Interventional Results available

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

NCT01190839
View directory record Official record
Conditions
Crohn's Disease
Interventions
Infliximab, Placebo
Biological · Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
62
States / cities
Birmingham, Alabama • La Jolla, California • Orange, California + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 17, 2026, 7:10 PM EDT
Completed Phase 2 Interventional

Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction

NCT06634030
View directory record Official record
Conditions
Wound Healing, Surgical Wound
Interventions
RhPDGF-BB, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
22 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 17, 2026, 7:10 PM EDT